Last C$0.64 CAD
Change Today -0.02 / -3.03%
Volume 16.0K
CZO On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 3:53 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

ceapro inc (CZO) Snapshot

Open
C$0.65
Previous Close
C$0.66
Day High
C$0.66
Day Low
C$0.62
52 Week High
12/3/14 - C$0.75
52 Week Low
12/20/13 - C$0.07
Market Cap
39.3M
Average Volume 10 Days
66.0K
EPS TTM
C$0.02
Shares Outstanding
61.4M
EX-Date
--
P/E TM
35.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for CEAPRO INC (CZO)

Related News

No related news articles were found.

ceapro inc (CZO) Related Businessweek News

No Related Businessweek News Found

ceapro inc (CZO) Details

Ceapro Inc., a biotechnology company, develops, commercializes, and markets health and wellness products, and technology relating to plant extracts in Canada, the United States, Germany, and other countries. The company markets natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; and veterinary therapeutic products, such as an oat shampoo, an ear cleanser, and a dermal complex/conditioner for veterinarians in Japan and Asia. Its products and technologies under research and development, or pre-commercial stage include CeaProve, a diabetes test meal to screen pre-diabetes and to confirm diabetes diagnosis; a drug delivery platform using its beta glucan technology delivers compounds for uses ranging from wound care and therapy to skin care treatments that reduce the signs of aging; an extension to the active ingredients product range; various novel manufacturing technologies; and new oat variety and technologies to increase the content of avenanthramides. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Founded in 1997

ceapro inc (CZO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$252.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: C$147.0K
Compensation as of Fiscal Year 2013.

ceapro inc (CZO) Key Developments

Ceapro Inc. Enters into Financing Agreement with Agriculture Financial Services Corporation

Ceapro Inc. announced that it has signed an Offer Letter with Agriculture Financial Services Corporation for a commercial financing of up to $900,000. Funds from AFSC's five-year term loan will be utilized for capital expenditures related to Ceapro's new 21,000 square foot GMP manufacturing relocation project which is nearing completion. The Company's new bio-processing extraction facility in Edmonton, Alberta, will have research and development, pilot scale and commercial production capabilities. The five year term loan with an interest rate of 3.84% is subject to standard conditions which are expected to be met by the Company within the near-term.

Ceapro Inc. Appoints William W. Li to Board of Directors

Ceapro Inc. announced that the company has appointed international health and disease management expert, William W. Li, M.D., to its Board of Directors. Dr. Li is the President, Medical Director and Co-founder of the Angiogenesis Foundation, and leads a worldwide revolution in diet and disease prevention based on emerging clinical research and technological advances. Through his work at the Angiogenesis Foundation, he has developed a unique social enterprise model based on international collaborations with medical academic centers, biopharmaceutical companies and government agencies, including the National Institutes of Health, National Cancer Institute and the Food and Drug Administration. Dr. Li's expertise extends across numerous medical specialties including oncology, hematology, cardiology, diabetes, ophthalmology, dermatology and wound care along with a diverse category of other disease areas and health conditions.

Ceapro Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Ceapro Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $2,444,956 compared to $1,997,398 a year ago. Income from operations was $730,978 compared to $198,298 a year ago. Net income for the period was $689,997 compared to $123,183 a year ago. Diluted EPS was $0.01. For the nine months, the company reported revenue of $6,831,039 compared to $5,021,999 a year ago. Income from operations was $1,778,094 compared to $446,309 a year ago. Net income for the period was $1,497,392 compared to $279,639 a year ago. Diluted EPS was $0.02.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CZO:CN C$0.64 CAD -0.02

CZO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CZO.
View Industry Companies
 

Industry Analysis

CZO

Industry Average

Valuation CZO Industry Range
Price/Earnings 28.1x
Price/Sales 4.7x
Price/Book 20.1x
Price/Cash Flow 28.1x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEAPRO INC, please visit www.ceapro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.